HLB bioStep Decides to Acquire 6 Billion Won of Its Own Convertible Bonds Before Maturity Due to Put Option Exercise, Eliminating 4.13% Potential Dilution
HLB bioStep decided on July 21, 2026 to acquire 6 billion won of its 4th unregistered unsecured private convertible bonds before maturity due to bondholders' exercise of put option.
The acquisition amount including principal and interest is 6.182 billion won, payable on August 20, 2026 from internal funds. The bonds will be cancelled at Korea Securities Depository.
These bonds were convertible into 750,938 shares 4.13% of outstanding at a conversion price of 7,990 won per share. The acquisition eliminates this potential dilution. Remaining convertible bonds of 4 billion won have a conversion price far above the current stock price of 2,100 won, making conversion unlikely.
The decision fulfills a financial obligation from the put option, positively impacting capital soundness but consuming cash reserves.
[AI Summary]HLB bioStep's pre-maturity acquisition of 6 billion won convertible bonds eliminates 4.13% potential dilution funded by internal cash. While this shows financial stability, the cash outflow is a one-time liquidity event. The remaining convertible bonds pose negligible conversion risk due to high exercise price, limiting further dilution concerns.
KOSDAQ Filing Information
Report On Major Events (Decision On Acquisition Before Maturity Of Self-Convertible Bonds)